TY - JOUR T1 - Urokinase-type Plasminogen Activator and Plasminogen-activator-inhibitor Type 1 Predict Metastases in Good Prognosis Breast Cancer Patients JF - Anticancer Research JO - Anticancer Res SP - 1475 LP - 1482 VL - 29 IS - 5 AU - PATRICIA DE CREMOUX AU - LAURE GRANDIN AU - VÉRONIQUE DIÉRAS AU - ALEXIA SAVIGNONI AU - ARMELLE DEGEORGES AU - RÉMY SALMON AU - MARC A. BOLLET AU - FABIEN REYAL AU - BRIGITTE SIGAL-ZAFRANI AU - ANNE VINCENT-SALOMON AU - XAVIER SASTRE-GARAU AU - HENRI MAGDELÉNAT AU - LAURENT MIGNOT AU - ALAIN FOURQUET AU - ON BEHALF OF THE BREAST CANCER STUDY GROUP OF THE INSTITUT CURIE Y1 - 2009/05/01 UR - http://ar.iiarjournals.org/content/29/5/1475.abstract N2 - This retrospective analysis was designed to confirm the predictive role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type I (PAI-1) in the outcome of early stage, node-negative breast cancer patients. Patients and Methods: Node-negative patients having not received adjuvant chemotherapy, and for whom frozen samples were available, were selected. Results: Among the 169 patients included, 56.8% presented with uPA >3 ng/mg of proteins and/or PAI-1 >14 ng/mg of proteins. The median follow-up was 73 months. Significant correlations were found between uPA and disease-free survival (p [univariate]=0.003; p [multivariate]=0.01), and between uPA, PAI-1, and uPA plus PAI-1 and distant relapses (p=0.002). No significant correlation was found between uPA/PAI-1 and the risk of locoregional recurrence. Conclusion: This study demonstrated that uPA and PAI-1 are useful predictors of distant metastases in a subset of early stage, node-negative breast cancer patients. ER -